natgillin/translations-raw huggingface dataset:
Biotransformation and elimination: Levodopa is extensively metabolised to various metabolites: decarboxylation by dopa decarboxylase (DDC) and O-methylation by catechol-O-methyltransferase (COMT) being the most important pathways. 
Biotransformacija in izločanje: Levodopa se v veliki meri presnavlja v različne presnovke, pri čemer sta najpomembnejši presnovni poti dekarboksilacija z dopa dekarboksilazo (DDK) in O-metilacija s katehol-O-metiltransferazo (COMT).
However, a direct switch from levodopa/DDC inhibitor to Levodopa/Carbidopa/Entacapone Orion is not recommended for patients who have dyskinesias or whose daily levodopa dose is above 800 mg. 
Neposreden prehod z levodope/zaviralcev DDK na zdravilo Levodopa/Carbidopa/Entacapone Orion pa ni priporočljiv pri bolnikih z diskinezijo ali pri tistih z dnevnim odmerkom levodope nad 800 mg.
As part of this PSUSA procedure, update of the levodopa/carbidopa/entacapone SmPCs with identical changes regarding dopamine dysregulation syndrome as agreed previously by the CMDh in the PSUSA process for levodopa/carbidopa containing products is considered warranted. 
Kot del tega postopka PSUSA je upravičena posodobitev SmPC-jev levodope/karbidope/entakapona z enakimi spremembami glede sindroma motene regulacije dopamina, kot je bilo prej dogovorjeno s CMDh v postopku PSUSA za zdravila, ki vsebujejo levodopo/karbidopo.
Not known (cannot be estimated from the available data) Craving for large doses of Levodopa/Carbidopa/Entacapone Orion in excess of that required to control motor symptoms, known as dopamine dysregulation syndrome. 
Neznana pogostnost (pogostnosti iz razpoložljivih podatkov ni mogoče oceniti) Potreba po visokih odmerkih zdravila Levodopa/Carbidopa/Entacapone Orion, ki presegajo odmerek, ustrezen za obvladovanje motoričnih simptomov, ki se imenuje sindrom motene regulacije dopamina.
Levodopa and entacapone may form chelates with iron in the gastrointestinal tract. 
Levodopa in entakapon lahko v prebavnem traktu tvorita kelate z železom.
NMS, including rhabdomyolysis and hyperthermia, is characterised by motor symptoms (rigidity, myoclonus, tremor), mental status changes (e.g., agitation, confusion, coma), hyperthermia, autonomic dysfunction (tachycardia, labile blood pressure) and elevated serum creatine phosphokinase. 
Za NMS, vključno z rabdomiolizo in hipertermijo, so značilni motorični simptomi (otrplost, mioklonus, tresenje), spremembe duševnega stanja (npr. vznemirjenost, zmedenost, koma), hipertermija, disfunkcija avtonomnega živčevja (tahikardija, labilen krvni tlak) in povišana vrednost serumske kreatin fosfokinaze.
Entacapone enhances the effects of levodopa. 
Entakapon poveča učinek levodope.
Antidepressants: Rarely, reactions including hypertension and dyskinesia have been reported with the concomitant use of tricyclic antidepressants and levodopa/carbidopa. 
Antidepresivi: Redka poročila navajajo reakcije, ki vključujejo hipertenzijo in diskinezijo v povezavi s sočasno uporabo tricikličnih antidepresivov in levodope/karbidope.
When used with Levodopa/Carbidopa/Entacapone Orion, the daily dose of selegiline should not exceed 10 mg. 
Ob sočasni uporabi z zdravilom Levodopa/Carbidopa/Entacapone Orion skupni dnevni odmerek selegilina ne sme presegati 10 mg.
Dopamine dysregulation syndrome (DDS) is described as a compulsive pattern of dopaminergic misuse above doses adequate to control motor symptoms. 
Sindrom motene regulacije dopamina (DDS) je opisan kot kompulzivna oblika zlorabe dopaminergičnih zdravil z odmerki, večjimi od tistih, ki so ustrezni za obvladovanje motoričnih simptomov.
Detailed information on this medicinal product is available on the website of European Medicines Agency: http://www.ema.europa.eu. 
Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila http://www.ema.europa.eu
Preclinical data of levodopa, carbidopa and entacapone, tested alone or in combination, revealed no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, and carcinogenic potential. 
Predklinični podatki za levodopo, karbidopo in entakapon bodisi samostojno ali v kombinaciji, ki so temeljili na standardnih študijah farmakološke varnosti, toksičnosti ponavljajočih se odmerkov, genotoksičnosti ali karcinogenosti, niso pokazali posebnega tveganja za človeka.
Your doctor may take some regular laboratory tests during a long term treatment with Levodopa/Carbidopa/Entacapone Orion. 
Zdravnik lahko izvede nekaj rednih laboratorijskih preiskav med dolgoročnim zdravljenjem z zdravilom Levodopa/Carbidopa/Entacapone Orion.
There are no adequate data from the use of the combination of levodopa/carbidopa/entacapone in pregnant women. 
Podatkov o uporabi kombinacije levodope/karbidope/entakapona pri nosečnicah ni.
Other forms of interactions: Since levodopa competes with certain amino acids, the absorption of Levodopa/Carbidopa/Entacapone Orion may be impaired in some patients on high protein diet. 
Druge oblike interakcij: Ker levodopa tekmuje (kompetitira) z nekaterimi aminokislinami, je lahko pri nekaterih bolnikih, ki uživajo visoko proteinsko dieto, absorpcija zdravila Levodopa/Carbidopa/Entacapone Orion motena.
Levodopa/Carbidopa/Entacapone Orion may have a major influence on the ability to drive and use machines. 
Zdravilo Levodopa/Carbidopa/Entacapone Orion ima pomemben vpliv na sposobnost vožnje in upravljanja strojev.
150 mg/37.5 mg/200 mg tablets, do not take more than 10 tablets per day. 
150 mg/37,5 mg/200 mg tablete, ne vzemite več kot 10 tablet dnevno.
Constipation*, vomiting*, dyspepsia, abdominal pain and discomfort*, dry mouth* 
zaprtost*, bruhanje*, dispepsija, abdominalni trebuh in nelagodje*, suha usta*
Because the effects of Levodopa/Carbidopa/Entacapone Orion tablets are equivalent with entacapone 200 mg tablet administered concomitantly with the commercially available standard release carbidopa/levodopa preparations in corresponding doses these results are applicable to describe the effects of Levodopa/Carbidopa/Entacapone Orion as well. 
Ker so učinki tablet zdravila Levodopa/Carbidopa/Entacapone Orion enaki kot pri tabletah entakapona 200 mg, uporabljenih sočasno z zdravili karbidope/levodope s standardnim sproščanjem v odgovarjajočih odmerkih, so ti rezultati uporabni tudi za prikaz učinkov zdravila Levodopa/Carbidopa/Entacapone Orion.
Therefore, do not take Levodopa/Carbidopa/Entacapone Orion and iron supplements at the same time. 
Zato ne jemljite zdravila Levodopa/Carbidopa/Entacapone Orion in železovih dodatkov sočasno.
Other antiparkinsonian medicinal products: To date there has been no indication of interactions that would preclude concurrent use of standard antiparkinsonian medicinal products with Levodopa/Carbidopa/Entacapone Orion therapy. 
Drugi antiparkinsoniki: Do sedaj niso znane nobene interakcije, ki bi omejevale sočasno uporabo standardnih antiparkinsonikov in zdravila Levodopa/Carbidopa/Entacapone Orion.
Very common (may affect more than 1 in 10 people) - uncontrolled movements (dyskinesias) - feeling sick (nausea) - harmless reddish-brown discolouration of urine - muscle pain - diarrhoea 
Zelo pogosti neželeni učinki (lahko se pojavijo pri več kot 1 od 10 bolnikov): - nekontrolirani gibi (diskinezije) - slabost (navzea) - neškodljivo rdečkastorjavo obarvanje urina - bolečina mišic - driska
- a liver problem, because your dose may need to be adjusted - kidney or hormone-related diseases - stomach ulcers or convulsions - if you experience prolonged diarrhoea consult your doctor as it may be a sign of inflammation of the colon - any form of severe mental disorder like psychosis - chronic wide-angle glaucoma, because your dose may need to be adjusted and the pressure in your eyes may need to be monitored. 
- bolezen ledvic, ali bolezni povezane s hormoni; - želodčno razjedo ali konvulzije (krče); - če pride do dolgotrajne driske, se posvetujte z zdravnikom, saj gre lahko za znak vnetja debelega črevesa; - kakršno koli obliko hude duševne motnje kot je psihoza; - če imate kronični glavkom odprtega zakotja, saj bo morda treba odmerek vašega zdravila prilagoditi in redno meriti vaš očesni tlak.
Entacapone in association with levodopa has been associated with isolated cases of excessive daytime somnolence and sudden sleep onset episodes. 
Entakapon v povezavi z levodopo povezujejo s posameznimi primeri pretirane somnolence čez dan in epizod nenadnega spanja.
c. When initiating Levodopa/Carbidopa/Entacapone Orion in patients currently treated with entacapone and levodopa/benserazide in a standard release formulation, the dosing of levodopa/benserazide should be discontinued in the previous night, and Levodopa/Carbidopa/Entacapone Orion should be started in the next morning. 
c. Ko se zdravljenje z zdravilom Levodopa/Carbidopa/Entacapone Orion uvaja pri bolnikih, ki trenutno prejemajo entakapon in levodopo/benzerazid s standardnim sproščanjem, je treba odmerjanje levodope/benzerazida eno noč ukiniti in naslednje jutro začeti dajati zdravilo Levodopa/Carbidopa/Entacapone Orion.
At the initiation, Levodopa/Carbidopa/Entacapone Orion should be adjusted to correspond as closely as possible to the total daily dose of levodopa currently used. 
Ob uvedbi zdravljenja je treba zdravilo Levodopa/Carbidopa/Entacapone Orion prilagoditi tako, da kar najbolj odgovarja skupnemu do sedaj uporabljanemu dnevnemu odmerku levodope.
If you must undergo surgery, please tell your doctor that you are using Levodopa/Carbidopa/Entacapone Orion. 
Če morate na operacijo, povejte svojemu zdravniku, da jemljete zdravilo Levodopa/Carbidopa/Entacapone Orion.
Patients taking these medicinal products with Levodopa/Carbidopa/Entacapone Orion should be carefully observed for loss of therapeutic response. 
Bolnike, ki jemljejo ta zdravila poleg zdravila Levodopa/Carbidopa/Entacapone Orion, je treba skrbno spremljati zaradi morebitnega zmanjšanja terapevtskega odgovora.
How to transfer patients taking levodopa/DDC inhibitor (carbidopa or benserazide) preparations and entacapone tablets to Levodopa/Carbidopa/Entacapone Orion a. Patients who are currently treated with entacapone and with standard release levodopa/carbidopa in doses equal to Levodopa/Carbidopa/Entacapone Orion tablet strengths can be directly transferred to corresponding Levodopa/Carbidopa/Entacapone Orion tablets. 
Kako preusmeriti bolnike, ki prejemajo levodopo/zaviralce DDK (karbidopo ali benzerazid) in entakapon tablete na zdravilo Levodopa/Carbidopa/Entacapone Orion a. Bolniki, ki trenutno prejemajo entakapon in levodopo/karbidopo s standardnim sproščanjem v odmerkih, ki po jakosti ustrezajo tabletam zdravila Levodopa/Carbidopa/Entacapone Orion, lahko neposredno preidejo na uporabo tablet zdravila Levodopa/Carbidopa/Entacapone Orion.
MARKETING AUTHORISATION NUMBER(S) 
ŠTEVILK(E) DOVOLJENJ(A) ZA PROMET
Few adverse reactions are known to be directly attributable to the active substance entacapone including diarrhoea and reddish-brown discolouration of urine. 
Znano je, da se lahko nekateri neželeni učinki pripišejo neposredno učinkovini entakapon, vključno z drisko in rdečkasto-rjavkastim obarvanjem urina.
Levodopa, the precursor of dopamine, crosses the blood brain barrier and relieves the symptoms of the disease. 
Levodopa, prekurzor v sintezi dopamina, prehaja skozi krvno-možgansko pregrado in lajša simptome bolezni.
Levodopa/Carbidopa/Entacapone Orion is used for the treatment of Parkinson's disease. 
Zdravilo Levodopa/Carbidopa/Entacapone Orion se uporablja za zdravljenje Parkinsonove bolezni.
Muscle spasms, arthralgia 
mišični spazmi, artralgija
Correspondingly, the decrease in daily OFF time was 24% in the entacapone group and 0% in the placebo group. 
Skladno s tem se je dnevno trajanje intervala, ko zdravilo ni delovalo, (»OFF«) pri skupini z entakaponom skrajšalo za 24 %, pri skupini s placebom pa za 0 %.
If this happens, you should not drive or use any tools or machines (see also section 'Driving and using machines') - notice that uncontrolled movements begin or get worse after you started to take Levodopa/Carbidopa/Entacapone Orion. 
Če se vam to zgodi, ne vozite in ne upravljajte strojev (glejte tudi poglavje »Vpliv na sposobnost upravljanja vozil in strojev«); - potem, ko ste začeli jemati zdravilo Levodopa/Carbidopa/Entacapone Orion, pojavijo nekontrolirani gibi, ali se ti pojavi poslabšajo.
Taking into account the PRAC Assessment Report on the PSUR for carbidopa/entacapone/levodopa, the scientific conclusions of the CHMP are as follows: 
Upoštevajoč poročilo Odbora za oceno tveganja na področju farmakovigilance (PRAC) o oceni rednih posodobljenih poročil o varnosti zdravila (PSUR) za carbidopo/entakapon/levodopo je Odbor za zdravila za uporabo v humani medicini (CHMP) sprejel naslednje znanstvene zaključke:
Levodopa/Carbidopa/Entacapone Orion and iron preparations should be taken at least 2-3 hours apart (see section 4.8). 
Zato je treba pri jemanju zdravila Levodopa/Carbidopa/Entacapone Orion in železovih pripravkov upoštevati najmanj 2-3 urni razmak med obema zdraviloma (glejte poglavje 4.8).
Due to short elimination half-lives, no true accumulation of levodopa or entacapone occurs on repeated administration. 
Zaradi kratkega razpolovnega časa izločanja ob ponovnih aplikacijah ne prihaja do večjega kopičenja levodope ali entakapona.
Discontinuation of Levodopa/Carbidopa/Entacapone Orion therapy: If Levodopa/Carbidopa/Entacapone Orion treatment (levodopa/carbidopa/entacapone) is discontinued and the patient is transferred to levodopa/DDC inhibitor therapy without entacapone, it is necessary to adjust the dosing of other antiparkinsonian treatments, especially levodopa, to achieve a sufficient level of control of the parkinsonian symptoms. 
Prekinitev zdravljenja z zdravilom Levodopa/Carbidopa/Entacapone Orion: Če je zdravljenje z zdravilom Levodopa/Carbidopa/Entacapone Orion (levodopa/karbidopa/entakapon) prekinjeno, bolnik pa namesto tega začne prejemati terapijo z levodopo/zaviralci DDK brez entakapona, je treba za dosego zadovoljive ravni obvladovanja parkinsonskih simptomov prilagoditi odmerjanje drugih antiparkinsonikov, zlasti levodope.
Tell your doctor if you experience any of these behaviours; they will discuss ways of managing or reducing the symptoms. 
Z njim se lahko pogovorite o možnostih obvladovanja takega vedenja oziroma zdravljenja simptomov.
Therefore Levodopa/Carbidopa/Entacapone Orion should be given cautiously to patients who are taking other medicinal products which may cause orthostatic hypotension. 
Zato je potrebna previdnost pri dajanju zdravila Levodopa/Carbidopa/Entacapone Orion bolnikom, ki jemljejo druga zdravila, ki lahko povzročajo ortostatsko hipotenzijo.
What Levodopa/Carbidopa/Entacapone Orion is and what it is used for What you need to know before you take Levodopa/Carbidopa/Entacapone Orion How to take Levodopa/Carbidopa/Entacapone Orion Possible side effects 
Kaj je zdravilo Levodopa/Carbidopa/Entacapone Orion in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Levodopa/Carbidopa/Entacapone Orion Kako jemljati zdravilo Levodopa/Carbidopa/Entacapone Orion Možni neželeni učinki
How to transfer patients not currently treated with entacapone to Levodopa/Carbidopa/Entacapone Orion 
Kako preusmeriti bolnike, ki trenutno ne prejemajo entakapona, na zdravilo Levodopa/Carbidopa/Entacapone Orion
Levodopa/Carbidopa/Entacapone Orion contains three active substances (levodopa, carbidopa and entacapone) in one film-coated tablet. 
Zdravilo Levodopa/Carbidopa/Entacapone Orion vsebuje tri učinkovine (levodopo, kabidopo in entakapon) v eni filmsko obloženi tableti.
If you suddenly stop taking of Levodopa/Carbidopa/Entacapone Orion and other antiparkinsonian medicines it may result in unwanted side effects. 
Če boste nenadno prenehali jemati tablete zdravila Levodopa/Carbidopa/Entacapone Orion in druge antiparkinsonike, lahko doživite neželene učinke.
For example, a patient taking one tablet of 50 mg/12.5 mg of levodopa/carbidopa with one tablet of entacapone 200 mg four times daily can take one 50 mg/12.5 mg/200 mg Levodopa/Carbidopa/Entacapone Orion tablet four times daily in place of their usual levodopa/carbidopa and entacapone doses. 
Na primer bolnik, ki prejema po eno tableto 50 mg/12,5 mg levodope/karbidope z eno tableto entakapona 200 mg 4-krat dnevno, lahko jemlje eno 50 mg/12,5 mg/200 mg tableto zdravila Levodopa/Carbidopa/Entacapone Orion 4-krat dnevno namesto običajnih odmerkov levodope/karbidope in entakapona.
Levodopa/Carbidopa/Entacapone Orion may increase the effects and side effects of certain medicines. 
Zdravilo Levodopa/Carbidopa/Entacapone Orion lahko poveča učinke in neželene učinke določenih zdravil.
Convulsions have occurred rarely with levodopa/carbidopa; however a causal relationship to levodopa/carbidopa therapy has not been established. 
Redko so se ob levodopi/karbodopi pojavile konvulzije, vendar pa vzročna zveza z levodopo/karbidopo ni bila potrjena.
- Levodopa/Carbidopa/Entacapone Orion is not recommended for the treatment of drug-induced extrapyramidal reactions. 
- Zdravilo Levodopa/Carbidopa/Entacapone Orion se ne priporoča za zdravljenje ekstrapiramidnih reakcij, ki jih povzročajo zdravila.
Total clearance for levodopa is in the range of 0.55-1.38 l/kg/h and for entacapone is in the range of 0.70 l/kg/h. 
Celokupen očistek levodope se giblje v razponu med 0,55-1,38 l/kg/h, entakapona pa okrog 0,70 l/kg/h.
Caution should be exercised when the following active substances are administered concomitantly with levodopa therapy. 
Previdnost je potrebna, kadar se sočasno z levodopo uporabljajo naslednje učinkovine:
Carbidopa is absorbed and eliminated slightly slower compared with levodopa. 
V primerjavi s levodopo se karbidopa absorbira in izloča nekoliko počasneje.
These include: - dopamine antagonists used to treat mental disorders, nausea and vomiting - phenytoin, used to prevent convulsions - papaverine used to relax the muscles. 
Taka zdravila so: - dopaminski antagonisti, ki se uporabljajo za zdravljenje duševnih motenj, slabosti in bruhanja - fenitoin, ki se uporablja za preprečevanje krčev - papaverin, ki se uporablja za mišično relaksacijo
Both levodopa and combinations of carbidopa and levodopa have caused visceral and skeletal malformations in rabbits. 
Tako levodopa kot tudi kombinacija karbidope in levodope so povzročile motnje v razvoju visceralnih organov in skeleta pri zajcih.
When given separately without the two other active substances, the bioavailability for levodopa is 15-33%, for carbidopa 40-70% and for entacapone 35% after a 200 mg oral dose. 
Pri samostojni aplikaciji peroralnega odmerka 200 mg brez ostalih dveh učinkovin je bila biološka uporabnost levodope 1533 %, karbidope 40-70 %, entakapona pa 35 %.
Tabulated list of adverse reactions 
b. Tabelarični pregled neželenih učinkov
Red iron oxide (E172) 
rdeči železov oksid (E172) saharoza titanov dioksid (E171) rumeni železov oksid (E172)
75 mg/18.75 mg/200 mg, 100 mg/25 mg/200 mg, 125 mg/31.25 mg/200 mg or 
75 mg/18,75 mg/200 mg, 100 mg/25 mg/200 mg, 125 mg/31,25 mg/200 mg ali
There are no significant differences in the AUC of carbidopa or entacapone between younger (45-64 years) and elderly (65-75 years). 
Med mlajšimi (45-64 let) in starejšimi (65-75 let) ni značilne razlike v AUC vrednostih karbidope ali entakapona.
Parkinsonism aggravated (e.g. bradykinesia)*, tremor, on and off phenomenon, dystonia, mental impairment (e.g. memory impairment, dementia), somnolence, dizziness*, headache 
poslabšanje parkinsonizma (npr. bradikinezija)*,tremor, fenomen vklop/izklop, distonija, duševna motnja (npr. motnja pomnjenja, demenca), somnolenca, omotica*, glavobol
Levodopa, carbidopa and entacapone together may cause dizziness and symptomatic orthostatism. 
Levodopa, karbidopa in entakapon skupaj lahko povzročajo vrtoglavico in simptomatsko ortostatsko hipotenzijo.
It may therefore be necessary, particularly in patients with dyskinesia, to reduce levodopa dose by 10-30% within the first days to first weeks after initiating Levodopa/Carbidopa/Entacapone Orion treatment. 
Zato bo morda potrebno v prvih dneh oziroma prvih tednih po uvedbi zdravljenja z zdravilom Levodopa/Carbidopa/Entacapone Orion, zlasti pri bolnikih z diskinezijo zmanjšati odmerek levodope za 10-30 %.
Antihypertensives: Symptomatic postural hypotension may occur when levodopa is added to the treatment of patients already receiving antihypertensives. 
Antihipertenzivi: Kadar se levodopa uvede v zdravljenje bolnikov, ki že prejemajo antihipertenzive, lahko pride do simptomatske posturalne hipotenzije.
If other levodopa products are used concomitantly with a Levodopa/Carbidopa/Entacapone Orion tablet, the maximum dose recommendations should be followed. 
Če se sočasno s tabletami zdravila Levodopa/Carbidopa/Entacapone Orion uporabljajo druga zdravila z levodopo, je treba upoštevati priporočila o največjem dovoljenem odmerjanju.
When less levodopa is required, the total daily dose of Levodopa/Carbidopa/Entacapone Orion should be reduced either by decreasing the frequency of administration by extending the time between doses, or by decreasing the strength of Levodopa/Carbidopa/Entacapone Orion at an administration. 
Kadar je potreben manjši odmerek levodope, se skupni dnevni odmerek zdravila Levodopa/Carbidopa/Entacapone Orion zmanjša bodisi z manj pogostimi odmerki, tako da se podaljša interval med posameznimi odmerki, ali pa z uporabo zdravila Levodopa/Carbidopa/Entacapone Orion manjše jakosti.
Fertility studies in animals have not been conducted with the combination of entacapone, levodopa and carbidopa. 
Študij na živalih o vplivu kombinacije entakapona, karbidope in levodope na plodnost niso opravili.
When considered necessary, the replacement of Levodopa/Carbidopa/Entacapone Orion with levodopa and DDC inhibitor without entacapone or other dopaminergic treatment should proceed slowly and an increase in levodopa dose may be necessary. 
Kadar je to potrebno, naj se zdravilo Levodopa/Carbidopa/Entacapone Orion nadomesti z levodopo in zaviralcem DDK brez entakapona postopoma, morda pa bo tudi potrebno povečati odmerek levodope.
Consult your doctor if during the treatment with Levodopa/Carbidopa/Entacapone Orion you: - notice that your muscles get very rigid or jerk violently, or if you get tremors, agitation, confusion, fever, rapid pulse, or wide fluctuations in your blood pressure. 
Posvetujte se z zdravnikom, če (se) med zdravljenjem z zdravilom Levodopa/Carbidopa/Entacapone Orion: - opazite, da postajajo mišice zelo toge ali silovito trzajo, če se začnete tresti, postanete vznemirjeni, zmedeni, dobite zvišano telesno temperaturo, zvišan srčni utrip ali se pojavi veliko nihanje krvnega tlaka.
Some patients experience severe abnormal involuntary movements (dyskinesias), mood swings or other side effects after taking large doses of Levodopa/Carbidopa/Entacapone Orion. 
Pri nekaterih bolnikih se pojavijo hudi nenormalni nehoteni gibi (diskinezija), nihanje razpoloženja ali drugi neželeni učinki, ki se pojavijo po jemanju visokih odmerkov zdravila Levodopa/Carbidopa/Entacapone Orion.
Pyridoxine, however, is not effective in reversing the actions of Levodopa/Carbidopa/Entacapone Orion. 
Vendar pa piridoksin ni učinkovit kot protisredstvo za delovanje zdravila Levodopa/Carbidopa/Entacapone Orion.
For adults and elderly: - Your doctor will tell you exactly how many tablets of Levodopa/Carbidopa/Entacapone Orion to take each day. 
Za odrasle in starejše: - Vaš zdravnik vam bo povedal, koliko tablet zdravila Levodopa/Carbidopa/Entacapone Orion morate vzeti vsak dan. - Tableta ni namenjena za deljenje ali drobljenje na manjše koščke.
Serious events of gastrointestinal haemorrhage (uncommon) and angioedema (rare) have been identified from the clinical trials with Levodopa/Carbidopa/Entacapone Orion or entacapone combined with levodopa/DDC inhibitor. 
Huda neželena učinka, gastrointestinalne krvavitve (občasno) in angioedem (redko), so opredelili v kliničnih preskušanjih z zdravilom Levodopa/Carbidopa/Entacapone Orion ali entakapon v kombinaciji z levodopo/zaviralcem dekarboksilaze.